Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Pattern and correlates of public support for public health interventions to reduce the consumption of sugar-sweetened beverages.

Bélanger-Gravel A, Desroches S, Janezic I, Paquette MC, De Wals P.

Public Health Nutr. 2019 Sep 23:1-11. doi: 10.1017/S1368980019002076. [Epub ahead of print]

PMID:
31544722
2.

Promoting vaccination in maternity wards ─ motivational interview technique reduces hesitancy and enhances intention to vaccinate, results from a multicentre non-controlled pre- and post-intervention RCT-nested study, Quebec, March 2014 to February 2015.

Gagneur A, Battista MC, Boucher FD, Tapiero B, Quach C, De Wals P, Lemaitre T, Farrands A, Boulianne N, Sauvageau C, Ouakki M, Gosselin V, Petit G, Jacques MC, Dubé È.

Euro Surveill. 2019 Sep;24(36). doi: 10.2807/1560-7917.ES.2019.24.36.1800641.

3.

Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch.

Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga JF, De Serres G, De Wals P.

Vaccine. 2019 Jul 18;37(31):4243-4245. doi: 10.1016/j.vaccine.2019.06.021. Epub 2019 Jun 22.

PMID:
31239214
4.

Kingdon's Multiple Streams Framework and the Analysis of Decision-Making Processes Regarding Publicly-Funded Immunization Programs.

De Wals P, Espinoza-Moya ME, Béland D.

Expert Rev Vaccines. 2019 Jun;18(6):575-585. doi: 10.1080/14760584.2019.1627208. Epub 2019 Jun 19.

PMID:
31216187
5.

A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease.

Marten O, Koerber F, Bloom D, Bullinger M, Buysse C, Christensen H, De Wals P, Dohna-Schwake C, Henneke P, Kirchner M, Knuf M, Lawrenz B, Monteiro AL, Sevilla JP, Van de Velde N, Welte R, Wright C, Greiner W.

Health Qual Life Outcomes. 2019 May 22;17(1):87. doi: 10.1186/s12955-019-1159-0.

6.

Middle ear abnormalities at age 5 years in relation with early onset otitis media and number of episodes, in the Inuit population of Nunavik, Quebec, Canada.

De Wals P, Lemeur JB, Ayukawa H, Proulx JF.

Int J Circumpolar Health. 2019 Dec;78(1):1599269. doi: 10.1080/22423982.2019.1599269.

7.

Promoting vaccination in the province of Québec: the PromoVaQ randomized controlled trial protocol.

Gagneur A, Quach C, Boucher FD, Tapiero B, De Wals P, Farrands A, Lemaitre T, Boulianne N, Sauvageau C, Ouakki M, Gosselin V, Gagnon D, Petit G, Jacques MC, Dubé È.

BMC Public Health. 2019 Feb 6;19(1):160. doi: 10.1186/s12889-019-6468-z.

8.

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations.

Acevedo R, Bai X, Borrow R, Caugant DA, Carlos J, Ceyhan M, Christensen H, Climent Y, De Wals P, Dinleyici EC, Echaniz-Aviles G, Hakawi A, Kamiya H, Karachaliou A, Lucidarme J, Meiring S, Mironov K, Sáfadi MAP, Shao Z, Smith V, Steffen R, Stenmark B, Taha MK, Trotter C, Vázquez JA, Zhu B.

Expert Rev Vaccines. 2019 Jan;18(1):15-30. doi: 10.1080/14760584.2019.1557520. Epub 2018 Dec 27. Review.

PMID:
30526162
9.

A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in Quebec.

Gilca R, De Wals P, Nolan SM, Kitchin N, Eiden JJ, Jiang Q, Jones CH, Jansen KU, Anderson AS, Pedneault L.

mSphere. 2018 Dec 5;3(6). pii: e00427-18. doi: 10.1128/mSphere.00427-18.

10.

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies.

Sings HL, De Wals P, Gessner BD, Isturiz R, Laferriere C, McLaughlin JM, Pelton S, Schmitt HJ, Suaya JA, Jodar L.

Clin Infect Dis. 2019 May 30;68(12):2135-2143. doi: 10.1093/cid/ciy920.

11.

Limited impact of pneumococcal vaccines on invasive pneumococcal disease in Nunavik (Quebec).

LeMeur JB, Lefebvre B, Proulx JF, De Wals P.

Can J Public Health. 2019 Feb;110(1):36-43. doi: 10.17269/s41997-018-0138-2. Epub 2018 Oct 19.

PMID:
30341482
12.

Overview of knowledge, attitudes, beliefs, vaccine hesitancy and vaccine acceptance among mothers of infants in Quebec, Canada.

Dubé È, Farrands A, Lemaitre T, Boulianne N, Sauvageau C, Boucher FD, Tapiero B, Quach C, Ouakki M, Gosselin V, Gagnon D, De Wals P, Petit G, Jacques MC, Gagneur A.

Hum Vaccin Immunother. 2019;15(1):113-120. doi: 10.1080/21645515.2018.1509647. Epub 2018 Sep 11.

13.

Commentary on paradoxical observations pertaining to the impact of the 13-valent pneumococcal conjugate vaccine on serotype 3 Streptococcus pneumoniae infections in children.

De Wals P.

Vaccine. 2018 Sep 5;36(37):5495-5496. doi: 10.1016/j.vaccine.2018.07.069. Epub 2018 Aug 1. No abstract available.

PMID:
30077481
14.

Prevalence of middle ear abnormalities from otitis media in relation with pneumococcal vaccine use in the Inuit population of Nunavik, province of Quebec, Canada.

Le Meur JB, Ayukawa H, Proulx JF, De Wals P.

Vaccine. 2018 Aug 16;36(34):5180-5186. doi: 10.1016/j.vaccine.2018.07.008. Epub 2018 Jul 17.

15.

A postpartum vaccination promotion intervention using motivational interviewing techniques improves short-term vaccine coverage: PromoVac study.

Gagneur A, Lemaître T, Gosselin V, Farrands A, Carrier N, Petit G, Valiquette L, De Wals P.

BMC Public Health. 2018 Jun 28;18(1):811. doi: 10.1186/s12889-018-5724-y.

17.

Individual and School Correlates of Adolescent Leisure Time Physical Activity in Quebec, Canada.

Massougbodji J, Lebel A, De Wals P.

Int J Environ Res Public Health. 2018 Feb 27;15(3). pii: E412. doi: 10.3390/ijerph15030412.

18.

Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.

De Wals P, Lefebvre B, Deceuninck G, Longtin J.

Vaccine. 2018 Jan 8;36(3):421-426. doi: 10.1016/j.vaccine.2017.11.054. Epub 2017 Dec 7.

PMID:
29224962
19.

Hospitalisation for lower respiratory tract infection in children in the province of Quebec, Canada, before and during the pneumococcal conjugate vaccine era.

Anderson G, Deceuninck G, Zhou Z, Boucher FD, Bonnier Viger Y, Gilca R, De Wals P.

Epidemiol Infect. 2017 Oct;145(13):2770-2776. doi: 10.1017/S0950268817001510. Epub 2017 Aug 14.

PMID:
28803551
20.

The Quebec experience in promoting healthy lifestyles and preventing obesity: how can we do better?

Le Bodo Y, Blouin C, Dumas N, De Wals P, Laguë J.

Obes Rev. 2017 Sep;18(9):967-986. doi: 10.1111/obr.12559. Epub 2017 May 30. Review.

PMID:
28557192
21.

Policy making for vaccine use as a driver of vaccine innovation and development in the developed world.

Seib K, Pollard AJ, de Wals P, Andrews RM, Zhou F, Hatchett RJ, Pickering LK, Orenstein WA.

Vaccine. 2017 Mar 7;35(10):1380-1389. doi: 10.1016/j.vaccine.2016.10.080. Review.

PMID:
28253995
22.

Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec.

Zhou Z, Deceuninck G, Lefebvre B, De Wals P.

Can J Infect Dis Med Microbiol. 2017;2017:4347206. doi: 10.1155/2017/4347206. Epub 2017 Jan 26.

23.

Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.

De Wals P, Deceuninck G, Lefebvre B, Tsang R, Law D, De Serres G, Gilca V, Gilca R, Boulianne N.

Clin Infect Dis. 2017 May 1;64(9):1263-1267. doi: 10.1093/cid/cix154.

PMID:
28207068
24.

Cost-effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada.

De Wals P, Zhou Z.

Pediatr Infect Dis J. 2017 Jul;36(7):e203-e207. doi: 10.1097/INF.0000000000001512.

PMID:
28027288
25.

The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection.

Borrow R, Alarcón P, Carlos J, Caugant DA, Christensen H, Debbag R, De Wals P, Echániz-Aviles G, Findlow J, Head C, Holt D, Kamiya H, Saha SK, Sidorenko S, Taha MK, Trotter C, Vázquez Moreno JA, von Gottberg A, Sáfadi MA; Global Meningococcal Initiative.

Expert Rev Vaccines. 2017 Apr;16(4):313-328. doi: 10.1080/14760584.2017.1258308. Epub 2016 Nov 22. Review.

PMID:
27820969
26.

Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.

De Wals P, Deceuninck G, De Serres G.

Vaccine. 2016 Apr 19;34(18):2053-4. doi: 10.1016/j.vaccine.2015.06.104. No abstract available.

PMID:
27021043
27.

Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections.

Jones CH, Mohamed N, Rojas E, Andrew L, Hoyos J, Hawkins JC, McNeil LK, Jiang Q, Mayer LW, Wang X, Gilca R, De Wals P, Pedneault L, Eiden J, Jansen KU, Anderson AS.

J Clin Microbiol. 2016 Jan;54(1):25-34. doi: 10.1128/JCM.01447-15. Epub 2015 Aug 26.

29.

Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.

Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P.

Vaccine. 2015 May 28;33(23):2684-9. doi: 10.1016/j.vaccine.2015.04.005. Epub 2015 Apr 15.

PMID:
25887086
30.

Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.

Montplaisir J, Petit D, Quinn MJ, Ouakki M, Deceuninck G, Desautels A, Mignot E, De Wals P.

PLoS One. 2014 Sep 29;9(9):e108489. doi: 10.1371/journal.pone.0108489. eCollection 2014.

31.

Uptake of pneumococcal vaccines in the Nordic region of Nunavik, province of Quebec, Canada.

Cléophat JE, Le Meur JB, Proulx JF, De Wals P.

Can J Public Health. 2014 May 30;105(4):e268-72.

PMID:
25166129
32.

Pediatric Pleural Empyema in the Province of Quebec: Analysis of a 10-Fold Increase Between 1990 and 2007.

Deceuninck G, Quach C, Panagopoulos M, Thibeault R, Côté-Boileau T, Tapiéro B, Coïc L, De Wals P, Ovetchkine P.

J Pediatric Infect Dis Soc. 2014 Jun;3(2):119-26. doi: 10.1093/jpids/pit075. Epub 2013 Dec 6.

PMID:
26625364
33.

Reviews examining sugar-sweetened beverages and body weight: correlates of their quality and conclusions.

Massougbodji J, Le Bodo Y, Fratu R, De Wals P.

Am J Clin Nutr. 2014 May;99(5):1096-104. doi: 10.3945/ajcn.113.063776. Epub 2014 Feb 26. Review.

PMID:
24572563
34.

Respiratory infection and otitis media visits in relation to pneumococcal conjugate vaccine use in Saskatchewan.

Khuc NH, Tan B, Tuchscherer R, Rawson NS, De Wals P.

Can J Infect Dis Med Microbiol. 2013 Winter;24(4):179-84.

35.

Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada.

De Wals P, Lefebvre B, Markowski F, Deceuninck G, Defay F, Douville-Fradet M, Landry M.

Vaccine. 2014 Mar 14;32(13):1501-6. doi: 10.1016/j.vaccine.2013.11.028. Epub 2014 Jan 31.

PMID:
24486346
36.

Impact of pneumococcal vaccines use on invasive pneumococcal disease in Nunavik (Quebec) from 1997 to 2010.

Le Meur JB, Lefebvre B, Proulx JF, Déry S, Pépin J, De Wals P.

Int J Circumpolar Health. 2014 Jan 17;73:22691. doi: 10.3402/ijch.v73.22691. eCollection 2014.

37.

Burden of rotavirus disease: A population-based study in Eastern Townships, Quebec.

Bernard S, Valiquette L, De Wals P, Nault V, Babakissa C, Cyr C, Boileau TC, Gagneur A.

Can J Infect Dis Med Microbiol. 2013 Fall;24(3):138-42.

38.

Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.

Vickers DM, Anonychuk AM, De Wals P, Demarteau N, Bauch CT.

Vaccine. 2015 Jan 1;33(1):268-75. doi: 10.1016/j.vaccine.2013.09.034. Epub 2013 Oct 6.

39.

Evaluation of several approaches to immunize parents of neonates against B. pertussis.

Frère J, De Wals P, Ovetchkine P, Coïc L, Audibert F, Tapiero B.

Vaccine. 2013 Dec 9;31(51):6087-91. doi: 10.1016/j.vaccine.2013.09.043. Epub 2013 Oct 5.

PMID:
24099874
40.

International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.

Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, Zuber P, Hua W, Bonhoeffer J, Buttery J, Crawford N, Deceuninck G, de Vries C, De Wals P, Gutierrez-Gimeno MV, Heijbel H, Hughes H, Hur K, Hviid A, Kelman J, Kilpi T, Chuang SK, Macartney K, Rett M, Lopez-Callada VR, Salmon D, Gimenez-Sanchez F, Sanz N, Silverman B, Storsaeter J, Thirugnanam U, van der Maas N, Yih K, Zhang T, Izurieta H; Global H1N1 GBS Consortium.

Vaccine. 2013 Sep 13;31(40):4448-58. doi: 10.1016/j.vaccine.2013.06.032. Epub 2013 Jun 14.

PMID:
23770307
41.

Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine.

Gilca V, De Serres G, Boulianne N, Murphy D, Ouakki M, De Wals P, Trudeau G, Massé R, Dionne M.

Hum Vaccin Immunother. 2013 Aug;9(8):1685-90. doi: 10.4161/hv.25015. Epub 2013 Jun 6.

42.

Factors associated with HPV vaccination among adult women in Quebec.

Kiely M, Sauvageau C, Dubé E, Deceuninck G, De Wals P.

Hum Vaccin Immunother. 2013 Jul;9(7):1421-4. doi: 10.4161/hv.24603. Epub 2013 Apr 9.

43.

The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains.

Gilca R, Deceuninck G, Lefebvre B, Tsang R, Amini R, Gilca V, Douville-Fradet M, Markowski F, De Wals P.

PLoS One. 2012;7(11):e50659. doi: 10.1371/journal.pone.0050659. Epub 2012 Nov 29.

44.

Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine.

Gilca V, De Serres G, Boulianne N, Murphy D, De Wals P, Ouakki M, Trudeau G, Massé R, Dionne M.

Vaccine. 2013 Jan 7;31(3):448-51. doi: 10.1016/j.vaccine.2012.11.037. Epub 2012 Dec 1.

PMID:
23206974
45.

The burden of childhood pneumonia in the developed world: a review of the literature.

Madhi SA, De Wals P, Grijalva CG, Grimwood K, Grossman R, Ishiwada N, Lee PI, Nascimento-Carvalho C, Nohynek H, O'Brien KL, Vergison A, Wolter J.

Pediatr Infect Dis J. 2013 Mar;32(3):e119-27. doi: 10.1097/INF.0b013e3182784b26. Review.

PMID:
23099423
46.

Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada.

De Wals P, Lefebvre B, Defay F, Deceuninck G, Boulianne N.

Vaccine. 2012 Oct 5;30(45):6416-20. doi: 10.1016/j.vaccine.2012.08.017. Epub 2012 Aug 21.

PMID:
22921290
47.

Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec.

De Wals P, Deceuninck G, Toth E, Boulianne N, Brunet D, Boucher RM, Landry M, De Serres G.

JAMA. 2012 Jul 11;308(2):175-81. doi: 10.1001/jama.2012.7342.

PMID:
22782419
48.

Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003.

Zhou J, Lefebvre B, Deng S, Gilca R, Deceuninck G, Law DK, De Wals P, Tsang RS.

J Clin Microbiol. 2012 May;50(5):1545-51. doi: 10.1128/JCM.06835-11. Epub 2012 Feb 15.

49.

[Human papilloma virus: knowledge, beliefs and behavior of Quebec women].

Kiely M, Sauvageau C, Dubé E, Deceuninck G, De Wals P.

Can J Public Health. 2011 Jul-Aug;102(4):303-7. French.

PMID:
21913589
50.

Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.

De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G.

Pediatr Infect Dis J. 2011 Jul;30(7):566-9. doi: 10.1097/INF.0b013e31820e8638.

PMID:
21326136

Supplemental Content

Support Center